12:00 AM
 | 
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nexavar sorafenib regulatory update

The U.K.'s NICE set a July 13 hearing date for 4 appeals against a final appraisal determination (FAD) that recommended against the use of 4 drugs to treat advanced and/or metastatic renal cell carcinoma (RCC). The FAD, which...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >